ANNOUNCEMENT

 

We are pleased to inform you that the study entitled The Plasma Proteins Market in the United States – 2014 is now available.

This report is a comprehensive market analysis of the therapeutic plasma and recombinant proteins sold in the U.S. in 2014. It provides sales data and historical trends, in units, dollars and market shares by company. Regulatory, economic and health care issues impacting the market are also analyzed. Plasma collections and fractionation, and products’ distribution are also covered.

Price upon request. The table of contents of the report is provided below.

 


 

THE PLASMA PROTEINS MARKET
IN THE UNITED STATES — 2014

 

TABLE OF CONTENTS

Page

 

 

1

 

14

15

23

23

 

43

43

46

47

47

 

61

62

66

67

68

69

77

83

 

85

 

85

97

97

102

105

107

107

109

112

117

 

117

117

118

119

120

124

125

126

131

 

139

139

140

141

 

146

147

152

157

160

173

175

185

193

 

195

 

203

 

203

 

208

 

213

 

219

219

221

222

225

226

228

231

 

233

 

 

 

 

EXECUTIVE SUMMARY

 

1) PLASMA COLLECTIONS

1.1) The Plasma Collection Sector

1.2) Source Plasma Safety

1.3) Major Plasma Collection Organizations

 

2) PLASMA FRACTIONATION

2.1)   Processing Capacity and Throughput

2.2)   Fractionation Plant Expansions

2.3)   Fractionation Production Cycle

2.5)   Production Yields

 

3) MARKET OVERVIEW

3.1)   The Plasma Proteins Market by Product

3.2)   Pricing Trends

3.3)   Product Mix

3.4)   The Plasma Fractions Market by Company

3.5)   Historical Development

3.6)   Products Marketing Approvals 2007-2013

3.7)   Products Marketing Approvals 2014 – mid 2015

 

4) IMMUNE GLOBULIN MARKET

4.1)   Intramuscular Polyvalent Immune Globulin Market and
Hyperimmune Globulin Products

4.2)   Polyvalent Intravenous Immune Globulin Market (IVIG)

4.2.1)         Polyvalent Intravenous Immune Globulin (IVIG) History

4.2.2)    Subcutaneous Immune Globulin (SCIG)

4.2.3)    Clinical Use of IVIG/SCIG

4.2.4)    IVIG and Alzheimer’s

4.2.5)    Market Development

4.2.6)    Results by Company

4.2.7)    IV/SCIG Pricing and Reimbursement

4.2.8)    IV/SCIG Distribution

 

5) ALBUMIN MARKET

5.1)   History of Albumin

5.2)   Clinical Use of Albumin

5.3)   Colloids vs. Crystalloids

5.4)   Albumin Safety Issues

5.5)   Non-Therapeutic Use of Albumin and Recombinant Albumin

5.6)   Therapeutic Apheresis Market

5.7)   Market Development

5.8)   Albumin Research Studies

 

6) HEMOPHILIA CARE MARKET

6.1)      Introduction

6.2)   Historical Development

6.3)   Hemophilia Patient Population

6.4)   Hemophilia Treatment Centers and
Pharmacy Benefit Management

6.5)   Historical review of coagulation factors development

6.6)   Clinical Development of Hemophilia Treatments

6.7)   Factor VIII Market Analysis

6.8)   Factor IX Market Analysis

6.9)   Von Willebrand Disease Market Analysis

6.10) Prothrombin Complex Market Analysis

6.11) Inhibitor Market Analysis

6.12) Other Bleeding Disorders

 

7) ALPHA-ONE ANTITRYPSIN MARKET

 

8) C-1 ESTERASE MARKET

 

9) ANTITHROMBIN III MARKET

 

10) FIBRIN SEALANT MARKET

 

11) OTHER PLASMA PRODUCTS

 

12) DISTRIBUTION OF PLASMA PRODUCTS

12.1) Overview

12.1.1)  Distribution channels by Product Line

12.1.2)  Group Purchase Organizations

12.1.3)  Wholesalers

12.1.4)  Drug Distributors

12.1.5)  Wholesalers & Dristibutors Contact Information

12.2) Specialty Pharmacies/Home Care Companies

 

13) PROFILES OF THE MAJOR FRACTIONATORS